Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2023-03-19 Investor Presentation
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Investor Presentation 24 pages 2.6MB
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation' and includes detailed information about the company's strategies, clinical pipeline, financials, and outlook. It explicitly states it is a presentation prepared for investors, not a regulatory filing or financial report. The content includes forward-looking statements, corporate summaries, clinical trial phases, and commercial examples, which are typical of investor presentations. There is no indication that this is an annual report, earnings release, or any other regulatory filing. The length (15,000 characters) and detailed content support it being a full investor presentation rather than a brief announcement or certification. Therefore, the document fits the category of Investor Presentation (IP).
2023-03-19 English
Neurotech to Present at NWR Virtual Healthcare Conference 1
Investor Presentation Classification · 90% confidence The document is an ASX announcement dated 20 March 2023 about Neurotech International Limited presenting at the NWR Virtual Healthcare Conference. It provides details about the presentation date, registration link, and company background. There is no financial data, no report attached or referenced as being published, and no mention of regulatory filings or certifications. The document is a straightforward announcement of an upcoming investor presentation event rather than the presentation itself or a financial report. Therefore, the most appropriate classification is Investor Presentation (IP) as it relates to a presentation for investors focusing on company strategy and market position, even though the actual presentation is upcoming and not included here. Confidence is high given the clear context and content.
2023-03-19 English
Phase I/II ASD Clinical Trials Results at 52 Weeks 12 pages 341.1KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 17 March 2023 from Neurotech International Limited. It reports detailed clinical trial results for a drug (NTI164) treating paediatric Autism Spectrum Disorder over a 52-week period. The text includes extensive clinical efficacy and safety data, statistical analysis, and commentary from company executives and clinical investigators. It is not a full annual or interim financial report, nor is it a regulatory filing or certification. It is a detailed update on clinical trial progress and results, which is typical of a Capital/Financing Update or clinical progress announcement. There is no indication of a shareholder meeting, voting results, or management changes. The document is lengthy (15,000 characters) and contains substantive data and analysis, not just a brief summary or presentation. Given the nature of the content focusing on clinical trial results and company development progress, the best fitting category is Capital/Financing Update (CAP), as it relates to company progress on a key development asset that impacts financing and valuation.
2023-03-16 English
Investor Presentation 26 pages 2.4MB
Investor Presentation Classification · 95% confidence The document is titled 'Phase I/II ASD 52 Week Results Investor Presentation' and is dated 17 March 2023. It contains detailed clinical trial results, safety and efficacy data, statistical analysis, and clinical interpretation related to a pharmaceutical product (NTI164) for Autism Spectrum Disorder. The content is structured as a presentation aimed at investors, including disclaimers, market size, trial design, and outcome measures. There is no indication that this is a regulatory filing, audit report, or earnings release. The document is not a full annual or interim financial report but rather a detailed presentation focusing on clinical trial results and business strategy. Therefore, the most appropriate classification is 'Investor Presentation' (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2023-03-16 English
Investor Conference Call - 52 Week Autism Study Results 2 pages 116.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 17 March 2023, primarily informing about an upcoming investor webcast and conference call regarding the 52 week Autism Spectrum Disorder study results. It provides details on how to register and participate in the call, including dial-in numbers and conference ID. There is no substantive financial data, analysis, or detailed report content included in the text. The document serves as a notification or invitation to a conference call rather than the transcript or report itself. Therefore, it fits best under the category of Call Transcript (CT) only if it contained the full transcript, but since it only announces the call, it is more appropriate to classify it as a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other categories. The document length is 3552 characters, which is short and consistent with an announcement rather than a full report or transcript.
2023-03-16 English
Trading Halt 2 pages 514.5KB
Regulatory Filings Classification · 95% confidence The document is a market announcement from Neurotech International Limited requesting a trading halt on its securities pending the release of clinical trial data. It references ASX Listing Rule 17.1 and is a formal request for a trading halt, not a financial report or earnings release. The content is short (2098 characters) and is clearly an announcement related to trading status rather than financial results or corporate governance changes. Therefore, it fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-03-14 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.